The FDA has gathered a group of medical experts together today to review and discuss Afrezza, an inhaled, rapid-acting insulin designed for the treatment of Type 1 and Type 2 diabetes. At the end of today's all-day meeting, the experts will vote on whether or not to recommend Afrezza's approval.
This is Mannkind's third attempt at getting Afrezza approved. The FDA rejected the product both times previously. For this resubmission, Mannkind conducted two phase III studies of Afrezza, one each in Type 1 and Type 2 diabetes.
TheStreet's biotech columnist Adam Feuerstein published a preview of today's panel on Monday.
Follow along all the action today as Feuerstein live blogs the Afrezza panel.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts